Excipients (fillers, binders), empty capsules, blister films and pharma glass (vials, ampoules, cartridges) - the non-active inputs in every finished dose.
Sigachi IndustriesDirect supplier · HighListed
Borosil ScientificDirect supplier · HighListed
SCHOTT PoonawallaDirect supplier · HighUnlisted
ACG WorldwideDirect supplier · HighUnlisted
ACG Worldwide
Unlisted maker of empty hard capsules, barrier films/foils and pharma processing and packaging machinery
Strengths
Among the world's largest empty-capsule makers, integrated with packaging films and equipment
Risks
Unlisted - no public market data
Background
Mumbai-based, family-owned with private-equity minority investors
Compiled from public reporting — not exchange-listed.
Where it fits
Supplies the inactive materials and primary packaging every finished dose needs: excipients like microcrystalline cellulose (MCC) that make up most of a tablet's weight, empty hard capsules, blister films and foils, and Type-I borosilicate glass vials, ampoules and cartridges for injectables.
Why it matters
These inputs are small in cost but impossible to skip: a formulation is registered with a specific excipient and container, so switching suppliers needs regulatory change filings. That makes qualified suppliers sticky - and makes injectable and GLP-1 growth a direct pull on pharma-glass capacity.
Where the value pool sits
Mid-teens to 20%+ EBITDA margins for qualified specialists. Volumes track global formulation output; pricing is helped by long qualification cycles but pressured by Chinese and European competitors in commodity grades.
Key drivers
Growth in injectables, prefilled syringes and GLP-1 pens (cartridges)
Generic volume growth and new plant commissioning in India
Import substitution of specialty excipients and glass
Potential bottlenecks
Type-I borosilicate glass tubing comes from a handful of global suppliers
Process-safety risk in powder handling (the June 2025 Sigachi Pashamylaram explosion)
Qualification with each customer takes 12-24 months